Jul 24, 2025 | Business, Chronic Disease, Diabetes, Disease Area Trends
For years, Eli Lilly’s main contributions to the Diabetes market were their insulins: fast-acting analog Humalog® and human insulin Humalin and two premix offerings in analog Humalog® Mix 50/50 and human premix Humalin 75/25. Despite a legacy category, this portfolio...
Jul 24, 2025 | Case Study, Case Study Forecasting
A multinational pharmaceutical firm asked Ozmosi to provide forecasts to assess the market impact of delays in delivering new formulation and packaging for an existing product. A planned reformulation seen as necessary to preserving market share had been delayed for...
Jul 24, 2025 | Case Study, Case Study Forecasting
The Asia-Pacific R&D unit of a large, multinational pharmaceutical company needed a pipeline prioritization approach to guide regional investment and development efforts to maximize continued growth. The portfolio team required a flexible approach that...
Jul 24, 2025 | Chronic Disease, Diabetes, Disease Area Trends
Diabetes is one of the most prevalent diseases in the U.S., afflicting over 29 million people across Type 1 and Type 2 patients, according to the CDC1 and represents over a $50 billion dollar industry2. Pharmaceutical companies are constantly racing to create the next...
Jul 24, 2025 | Case Study, Market Scan
A regional marketing team for a multinational pharmaceutical company needed a complete market overview of a neuroscience therapy area within the Asia Pacific region. This overview had both internal and external perspectives covering the science, competitive and...
